Baseline characteristics of patients with SVR and those without SVR in the normal ALT group
| Patients without SVR (n=32) | Patients with SVR (n=20) | p Value | |
|---|---|---|---|
| SVR, sustained virological response; BMI, body mass index; ALB, albumin; BIL, bilirubin; ALT, alanine aminotransaminase; AST, aspartate aminotransaminase; ALP, alkaline phosphatase; HCV, hepatitis C virus. | |||
| Values are median (interquartile range 25th–75th percentile) or number. | |||
| Age (y) | 47.5 (44–53) | 47.5 (43–51) | 0.90 |
| Sex (M:F) | 29:3 | 17:3 | 0.66 |
| Genotype | 0.03 | ||
| 1 | 24 | 9 | |
| Non-1 | 8 | 11 | |
| (2) | (4) | (5) | |
| (3) | (2) | (4) | |
| (Indeterminate) | (2) | (2) | |
| BMI (kg/m2) | 27.4 (24.4–29.2) | 26.6 (22.4–34.2) | 0.24 |
| ALB (g/l) | 4 (4–4.2) | 3.8 (3.8–4.1) | 0.08 |
| BIL (mg/dl) | 0.8 (0.6–1.0) | 0.7 (0.5–0.8) | 0.09 |
| ALT (U/l) | 47 (40–53) | 50 (41–55) | 0.49 |
| AST (U/l) | 46 (32–54) | 47 (39–51) | 0.85 |
| ALP (U/l) | 70 (57–90) | 67 (57–87) | 0.98 |
| HCV RNA (IU/ml) | 450 000 (83 000–>850 000) | 420 000 (75 020–>850 000) | 0.94 |
| Stage of fibrosis | 0.66 | ||
| F0–F1 | 14 | 10 | |
| F2–F3 | 18 | 10 | |